Tolvaptan Sodium Phosphate Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Tolvaptan Sodium Phosphate Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Tolvaptan Sodium Phosphate can convert its Small molecule drug profile and AVPR2 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Tolvaptan Sodium Phosphate (query alias: Tolvaptan Sodium Phosphate) |
|---|---|
| Modality / target | Small molecule drug; AVPR2; AVPR2 antagonists |
| Highest global status | Approved |
| Originator | Otsuka Pharmaceutical Co., Ltd. |
| Active developers | Otsuka Pharmaceutical Co., Ltd., Fuji Yakuhin Co., Ltd. |
The MCP disease footprint includes Body fluid retention, Heart Failure, Edema, Cardiac. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT05712746 | Not Applicable | Active, not recruiting | 1600 | Safety information (Adverse Event) |
| CTR20261411 | Not Applicable | 已完成 | 32 | Not disclosed |
| JPRN-jRCTs031230062 | Not Applicable | Recruiting | 32 | Effect of Samtas use on fluid retention (change in body weight and urine output (% change in urine output per kg body weight) from baseline (before Samtas administration) to last dose) |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A Phase I, Open-Label Trial to Assess the Mass Balance and Pharmacokinetics of a Single Intravenous Administration of (14C)-OPC-61815 to Healthy Male Japanese Subjects
Phase 1; n=8; evaluation: not stated. Reported fields: -; Area Under the Concentration-time Curve From Time Zero to Infinity (AUC∞) - Plasma OPC-61815 Free Form(Mean) = 2060 h*ng/mL (Standard Deviation, 305); -
A Multicenter, Open-label, Uncontrolled Clinical Trial to Confirm the Tolerability of OPC-61815 in Patients With Congestive Heart Failure Who Have Difficulty With or Are Incapable of Oral Intake
Phase 3; n=45; evaluation: not stated. Reported fields: Percentage of Subjects With Treatment-Emergent Adverse Events (TEAEs) and Serious TEAEs = 77.8 percentage of participants ; -; -
A Multicenter, Double-blind, Randomized, Active-controlled, Parallel-group, Non-inferiority Trial to Evaluate the Efficacy and Safety of OPC-61815 Injection Compared With Tolvaptan 15-mg Tablet in Patients With Congestive Heart Failure
Phase 3; n=294; evaluation: not stated. Reported fields: Change From Baseline in Body Weight(Least Squares Mean) = -1.67 kg (95% Confidence Interval, -1.93 to -1.41); -; Change From Baseline in Body Weight(Least Squares Mean) = -1.36 kg (95% Confidence Interval, -1.62 to -1.10)
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Tolvaptan Sodium Phosphate addresses Body fluid retention, Heart Failure, Edema, Cardiac. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 13 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: AVPR2 records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-04-23 | Apotex Completes Previously Announced Strategic Transaction with Cumberland Pharmaceuticals | Approved | Financial terms not disclosed |
| 2025-01-14 | Ferring Pharma and Kissei Pharmaceutical announce that they will terminate their co-promotion agreement for "Minirin Melt®" and "Desmopressin formulations" | Approved | Financial terms not disclosed |
| 2023-03-15 | Eton Pharmaceuticals has acquired the rare disease product candidate ET-600 from Tulex Pharmaceuticals for the treatment of a pediatric endocrinology condition in the United States | Not disclosed | Financial terms not disclosed |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Therapeutic index across KRAS/BRAF mutation subgroups
- On-target toxicity and adaptive MAPK resistance
- Lack of matched efficacy results in the current MCP result set
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
